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Background: Invasive breast cancers are now commonly classified using gene expression into biologically and
clinically distinct tumor subtypes. However, the role of obesity in breast tumor gene expression and intrinsic
subtype is unknown.
Methods: Early-stage breast cancer (BC) patients (n = 1,676) were sampled from two prospective cohorts. The
PAM50 qRT-PCR assay was used to: a) assess tumor gene expression levels for ESR1, PGR, ERBB2, and 10 proliferation
genes and b) classify tumors into intrinsic subtype (Luminal A, Luminal B, Basal-like, HER2-enriched, Normal-like).
Body mass index (BMI) around BC diagnosis (kg/m2) was categorized as: underweight (<18.5), normal (18.5-24),
overweight (25–29), mildly obese (30–34), and highly obese (≥35). In a cross-sectional analysis, we evaluated associations
of BMI with gene expression using linear regression models, and associations of BMI with non-Luminal A intrinsic
subtypes, compared with Luminal A subtype, using multinomial logistic regression. Statistical significance tests were
two-sided.
Results: Highly obese women had tumors with higher expression of proliferation genes compared with normal weight
women (adjusted mean difference = 0.44; 95% CI: 0.18, 0.71), yet mildly obese (adjusted mean difference = 0.16; 95%
CI: −0.06, 0.38) and overweight (adjusted mean difference = 0.18; 95% CI: −0.01, 0.36) women did not. This association was
stronger in postmenopausal women (p for interaction = 0.06). Being highly obese, however, was inversely associated with
ESR1 expression (adjusted mean difference =−0.95; 95% CI: −1.47, −0.42) compared with being normal weight, whereas
being mildly obese and overweight were not. In addition, women with Basal-like and Luminal B subtypes, relative to
those with Luminal A subtype, were more likely to be highly obese, compared with normal-weight.
Conclusions: ER expression may not increase correspondingly with increasing degree of obesity. Highly obese patients
are more likely to have tumor subtypes associated with high proliferation and poorer prognosis.
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Invasive breast cancers are now commonly classified
using gene expression into biologically and clinically dis-
tinct tumor subtypes known as Luminal A, Luminal B,
Basal-like, and HER2-Enriched (HER2-E) [1,2]. Subtype
information has been shown to be an independent pre-
dictor of breast cancer survival when used in multivariate* Correspondence: Marilyn.L.Kwan@kp.org
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unless otherwise stated.analyses including standard clinicopathologic variables
[3-6]. In 2009, Parker et al. derived a minimal gene set
(PAM50) for classifying “intrinsic” subtypes of breast can-
cer [6,7]. The PAM50 gene set has high classification
agreement with larger “intrinsic” gene sets previously used
for subtyping [1,2,4,6], and is a feasible assay for applica-
tion in clinical and epidemiologic studies that routinely
use processed tumor tissue [8].
Substantial evidence suggests that obese women are at
greater risk of postmenopausal breast cancer and have
poorer breast cancer survival compared with normal-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor development via increased estradiol production in
adipose tissue in postmenopausal women, higher insulin
levels, cellular interaction of leptin with insulin, and a
constant pro-inflammatory state [17,18]. However, to
our knowledge, the relationship between obesity before
cancer diagnosis and likelihood of a specific tumor gene
profile has not been examined. Therefore, in a cohort of
1,676 breast cancer survivors derived from two large
prospective cohort studies, we explored cross-sectional
associations of body mass index (BMI) around breast
cancer diagnosis with PAM50-derived tumor expression
of selected genes (ESR1, PGR, ERBB2, and proliferation)
and intrinsic subtype.Methods
Study population
The underlying study population was women from the
LACE (PI: BJ Caan, [19]) and Pathways (PI: LH Kushi,
[20]) prospective cohort studies of breast cancer survivors.
A total of 2,135 LACE participants were 18–79 years old
when diagnosed with early-stage breast cancer from
1997–2000 (AJCC stage I with tumor size ≥1 cm, stage II,
or stage IIIA) and were identified primarily from the
KPNC Cancer Registry (83%) or the Utah Cancer Registry
(12%). Additional eligibility criteria included: being within
39 months of diagnosis to study enrollment (mean time =
23 months, 61% between 12 and 24 months), completion
of chemotherapy or radiotherapy, no prior history of
breast cancer or other cancer in the last 5 years.
The Pathways Study enrolled 4,505 women diagnosed
with AJCC Stage I-IV breast cancer from 2006–2013 at
KPNC with no previous diagnosis of other invasive
cancer, at least 21 years of age at diagnosis, and spoke
English, Spanish, or Chinese. Most women were
approached for enrollment within two months of diag-
nosis (mean time = 1.8 months, range = 0.3-7.2 months).
Participants provided informed consent under human
subjects’ protocols approved by the institutional review
boards (IRB) at KPNC (CN-98BCaan-04-H) and the
University of Utah (IRB_00038002). All human subjects’
research carried out in this study was in compliance
with the Helsinki declaration (http://www.wma.net/en/
30publications/10policies/b3/index.html).Clinicopathologic characteristics
Clinicopathologic characteristics at cancer diagnosis, in-
cluding disease stage, tumor size, nodal status, grade, es-
trogen receptor (ER) status, progesterone receptor (PR)
status, and human epidermal growth factor receptor 2
(Her2) overexpression or amplification in the primary
tumor, were abstracted from cancer registry data and
medical record review.Obesity and other covariates
Demographic and breast cancer risk factor data were
collected at study enrollment on a mailed questionnaire
(LACE) or in-person interview (Pathways),and included
age at breast cancer diagnosis, race/ethnicity, education,
menopausal status, smoking, and moderate-vigorous
physical activity (metabolic equivalent (MET)-hours/
week).
LACE women were asked to self-report their weight
and height at 12 months before breast cancer diagnosis
on the baseline questionnaire, which as completed on
average 2 years post-diagnosis. Pathways women were
asked to self-report their weight and height at the time
of the baseline interview, conducted on average 2 months
after breast cancer diagnosis. Then a BMI value which
represents the period around breast cancer diagnosis
was computed from these self-reported weight and
height values, and categorized according to WHO inter-
national guidelines as a 5-level variable based on our
previous work in obesity and breast cancer survival
[21,22]. These categories (kg/m2) are: underweight
(<18.5), normal (18.5-24), overweight (25–29), mildly
obese (30–34), and highly obese (≥35).Sampling strategy for PAM50 assay
For the PAM50 ancillary study (PI: BJ Caan), the LACE
and Pathways cohorts were pooled with the overall goal
to evaluate the performance of the PAM50 assay in a
population-based study where patient characteristics,
treatment patterns, and time of initial follow-up varied
[23]. All LACE women from KPNC and Utah were eli-
gible for the sub-study (n = 2,135), whereas Pathways
women diagnosed from 2006–2008 were eligible (n =
2,172).
To further select eligible women for the PAM50 assay
given limited study resources, we used a stratified case-
cohort study design [24], with strata defined by clinical
subtype based on immunohistochemistry (IHC) results
for ER, PR, and Her2 [25]. The subcohort consisted of a
random sample of women with the most common IHC
subtype (ER+ or PR+, Her2-) (sampling fraction = 18%),
and all women with the remaining less common sub-
types having worse prognosis (ER+ or PR+, Her2+; ER-,
PR-, Her2-; and ER-, PR-, Her2+) (sampling fraction =
100%). The cohort was followed for recurrence and sur-
vival through August 2013. Women who were not part
of the subcohort but had an outcome of interest during
this time were included. Out of 2,087 women selected
for the case-cohort, 1,691 had tumor tissue successfully
assayed by the PAM50. For this analysis, an additional
15 women were excluded due to missing BMI values,
thus a total of n = 1,676 women comprised the final ana-
lytic sample with PAM50 data.
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For those selected into the case-cohort study, we ob-
tained formalin-fixed, paraffin-embedded (FFPE) tissue
blocks and corresponding slides from the surgical hos-
pital or pathology storage facility. Slides were reviewed
by one pathologist (R.E.F.). If the area of invasive tumor
was observed to be smaller than 0.5 cm in diameter, the
case was classified as ineligible. Tissue punches 1 mm in
diameter were obtained from an area of the FFPE tissue
block corresponding to the marked slide.
Gene expression assay and PAM50 intrinsic subtypes
Real-time reverse-transcription PCR (qRT-PCR) was
conducted for the 50 target genes that comprise the
PAM50 intrinsic subtype classifier [6], and details have
been provided elsewhere [26,27]. Laboratory personnel
(I.J.S.) were blinded to clinical information and received
only a study identification number to track the sample.
The PAM50 assay yields an expression value for each
gene that is relative to a reference gene. The raw data in-
clude both positive and negative values. For ease of in-
terpretation of summary statistics, we transformed the
values by adding 10 to all scores prior to analysis to
make all values positive while preserving rank order. To
determine intrinsic subtypes from the gene expression
data, we applied centroid-based algorithms to the cali-
brated log-expression ratio for the 50 genes in the entire
PAM50 assay. For each sample, this process generates
five continuous-scale normalized subtype scores repre-
senting degree of Spearman correlation of gene expres-
sion with that of prototype Luminal A, Luminal B,
Basal-like, HER2-E, and Normal-like breast tumors
[6,26]. The subtype with the highest score became the
predicted intrinsic subtype for that case.
Quantitative expression of individual genes that are
standard breast cancer prognostic biomarkers (ESR1,
PGR, ERBB2) were selected as variables of interest. Ex-
pression of 10 cell cycle regulation genes was averaged
into a cell proliferation value (CENPF, ANLN, CDC20,
CCNB1, CEP55, MYBL2, MKI67, UBE2C, RRM2, KIF2C).
Statistical analysis
All analyses incorporated sampling weights and the
stratified sampling design for unbiased estimation of
population parameters and valid estimates of standard
errors [28,29]. This includes estimates of frequency dis-
tributions and chi-square tests of baseline characteristics
and regression analyses using the ‘svy’ commands in
Stata software, StataCorp, College Station, TX. Statistical
significance tests were two-sided.
We described associations of obesity with intrinsic
subtypes by fitting a multinomial logistic regression
model. This method is similar to the case-case analysis ap-
proach widely used for dichotomous tumor characteristics[30], extended to the five subtype categories via the multi-
nomial model. Treating the most prevalent subtype, Lu-
minal A, as the base comparator outcome, we estimated
odds ratios (OR) and 95% confidence intervals (CI) associ-
ated with BMI categories for each of the non-Luminal A
subtypes. We also used multiple linear regression for point
and interval estimation of adjusted differences in mean
gene expression levels across BMI categories.
All models were adjusted for age at diagnosis, race/
ethnicity, moderate-vigorous physical activity, and AJCC
stage. Given that associations between obesity and breast
cancer risk differ by menopausal status [31], models
were also stratified by menopausal status (premeno-
pausal vs. postmenopausal). In the non-stratified models,
effect modification was evaluated by calculating p values
for interaction via cross-product terms of BMI as a con-
tinuous variable and menopausal status.
All models were also run individually by cohort, and
results were largely consistent with the combined cohort
(Additional files 1 and 2), thus we present findings for
the combined cohort below.
Results
The distributions of demographic, clinical, and PAM50
intrinsic subtype by BMI are given in Table 1. Among
the highly obese (≥35 kg/m2) and underweight
(<18.5 kg/m2) groups, Basal-like subtypes were more
common (18.9% and 22.6%, respectively), compared with
the other BMI groups (8%-10%), whereas Luminal A was
less common (36.3% and 33.9%, respectively), compared
with the other groups (49%-56%). African American
women were more likely to be highly obese (14.9%) and
less likely to be normal weight, overweight, or mildly
obese (3.7%-8.7%), whereas White women were more
likely to be normal weight, overweight, or mildly obese
(74.2%-75.1%) and less likely to be highly obese (59.4%).
Both the highly obese and underweight groups had
noticeably lower levels of moderate-vigorous physical ac-
tivity (67.6% and 66.7% below median 18.9 MET-hours/
week, respectively), in contrast to the other BMI groups
that had higher (normal weight) or similar (overweight
and mildly obese) levels relative to the median level. The
normal-weight women had less comorbidities (9.1%)
whereas the underweight women had more comorbidi-
ties (22.6%), compared with the other BMI groups
(9.1%-18.2%).
ESR1 and proliferation unadjusted gene expression
levels varied by BMI category, whereas there were no
significant differences for PGR and ERBB2 levels
(Table 2). Women who were highly obese or under-
weight had lower ESR1 gene expression (highly obese
mean = 11.54, underweight mean = 10.95; p = 0.03) yet
higher expression of proliferation genes (highly obese
mean = 9.12, underweight mean = 9.07; p = 0.02), relative
Table 1 Demographic and clinical characteristics by BMI around breast cancer diagnosis, LACE and Pathways cohorts
Underweight Normal weight Overweight Mildly Obese Highly Obese Total p valuea
<18.5 kg/m2 18.5-24.9 kg/m2 25.0-29.9 kg/m2 30-34.9 kg/m2 ≥35.0 kg/m2
n=13 n=658 n=509 n=290 n=206 n=1,676
Age at breast cancer diagnosis (years) 0.04
<50 49.2% 24.6% 20.0% 23.1% 18.3% 22.4%
50-64 28.2% 48.1% 43.9% 42.2% 58.2% 46.7%
≥65 22.6% 27.3% 36.1% 34.7% 23.5% 30.9%
Race/Ethnicity <0.0001
White 88.7% 74.2% 74.1% 75.1% 59.4% 72.8%
African American 0.0% 3.7% 5.3% 8.7% 14.9% 6.3%
Hispanic 0.0% 5.2% 9.8% 9.4% 18.7% 8.8%
Asian 11.3% 14.6% 9.5% 4.3% 2.2% 9.7%
Other 0.0% 2.4% 1.4% 2.5% 4.9% 2.3%
Menopausal status at breast cancer diagnosis 0.37
Postmenopausal 45.2% 67.2% 71.1% 70.7% 72.5% 69.5%
Premenopausal 54.8% 24.8% 22.7% 25.8% 21.9% 24.2%
Unknown 0.0% 8.0% 6.2% 3.6% 5.5% 6.3%
Education <0.0001
High school or less 16.9% 15.1% 25.3% 26.7% 20.1% 20.9%
Some college 22.6% 34.4% 36.7% 42.2% 49.2% 38.1%
College graduate 49.2% 24.3% 21.8% 17.1% 14.2% 21.2%
Post-graduate 11.3% 26.2% 16.1% 14.0% 16.5% 19.7%
Smoking history at breast cancer diagnosis 0.65
Never 28.2% 55.3% 50.9% 53.1% 50.2% 52.9%
Past 66.1% 38.7% 42.7% 39.2% 46.0% 40.9%
Current 5.6% 6.0% 6.4% 7.7% 3.8% 6.2%
Moderate-vigorous physical activity before breast
cancer diagnosis (median=18.9 MET-hrs/wk)
<0.0001
Below Median 66.7% 38.0% 51.0% 58.6% 67.6% 49.2%
Above Median 33.3% 62.0% 49.0% 41.4% 32.4% 50.8%
AJCC stage 0.20
I 39.5% 52.3% 50.7% 49.4% 40.5% 49.9%
II 54.8% 41.7% 42.8% 39.9% 49.9% 42.6%
III 5.6% 5.6% 5.6% 10.5% 9.1% 6.9%
IV 0.0% 0.4% 0.9% 0.2% 0.6% 0.5%
Any comorbidity (Charlson comorbidity index) 0.01
No 77.4% 90.9% 81.8% 86.4% 83.0% 86.4%
Yes 22.6% 9.1% 18.2% 13.6% 17.0% 13.6%
PAM50 intrinsic subtype 0.01
Luminal A 33.9% 55.9% 49.2% 56.2% 36.3% 51.7%
Luminal B 37.9% 17.8% 23.4% 18.3% 26.6% 20.7%
Basal-like 22.6% 8.0% 9.8% 10.4% 18.9% 10.3%
HER2-E 5.6% 14.5% 13.6% 11.1% 17.1% 13.8%
Normal 0.0% 3.7% 4.0% 4.0% 1.1% 3.6%
Note: Percentages are weighted due to stratified case-cohort study design with strata defined as IHC clinical subtype.
aFrom Pearson chi-square tests.
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Table 2 PAM50 gene expression levels by BMI around breast cancer diagnosis and menopausal status, LACE and
Pathways cohorts
Underweight Normal weight Overweight Mildly Obese Highly Obese p valuea
<18.5 kg/m2 18.5-24.9 kg/m2 25.0-29.9 kg/m2 30-34.9 kg/m2 ≥35.0 kg/m2
mean mean mean mean mean
n=13 n=658 n=509 n=290 n=206
Overall (n=1,676)
ESR1 10.95 12.31 12.32 12.43 11.54 0.03
PGR 6.73 7.98 7.82 8.33 7.76 0.86
ERBB2 13.18 13.84 13.78 13.71 13.68 0.08
Proliferation 9.07 8.64 8.75 8.79 9.12 0.02
Premenopausal (n=428)
ESR1 10.61 11.93 11.78 11.70 10.78 0.01
PGR 7.57 7.74 7.51 8.44 7.64 0.79
ERBB2 12.84 13.76 13.96 13.87 13.42 0.32
Proliferation 9.62 9.16 9.17 9.13 9.15 0.85
Postmenopausal (n=1,135)
ESR1 11.37 12.50 12.54 12.73 11.80 0.17
PGR 5.71 8.01 7.96 8.31 7.77 0.76
ERBB2 13.59 13.87 13.73 13.67 13.76 0.15
Proliferation 8.40 8.49 8.60 8.66 9.09 0.01
NOTE: Raw values are re-scaled by adding a constant of 10 units to interpret and preserve rank order.
a P values from generalized linear model (GLM) for gene expression.
Kwan et al. BMC Cancer  (2015) 15:278 Page 5 of 10to women in the other BMI categories. When stratifying
by menopausal status, lower ESR1 expression in the
highly obese (mean = 10.78) and underweight (mean =
10.61) continued to be observed in premenopausal
women only (p = 0.01), whereas higher proliferation ex-
pression was seen in postmenopausal women who were
highly obese (mean = 9.09) but not underweight (mean =
8.40, p = 0.01).
The adjusted mean differences in expression of ESR1,
PGR, ERBB2, and proliferation genes by BMI category
are given in Table 3. In models adjusted for age, race/
ethnicity, moderate-vigorous physical activity, AJCC
stage, and study, women who were highly obese
(≥35 kg/m2) had tumors with 0.37 standard deviation
(SD) higher expression of proliferation genes vs. normal-
weight women (adjusted mean difference = 0.44; 95% CI:
0.18, 0.71), yet expression levels were fairly similar at
0.13 SD for the mildly obese (30.0-34.9 kg/m2) vs.
normal-weight women (adjusted mean difference = 0.16;
95% CI: −0.06, 0.38). By contrast, the highly obese group
had 0.34 SD lower expression of ESR1 compared with
normal-weight women (adjusted mean difference = −0.95;
95% CI: −1.47, −0.42). Furthermore, compared with
normal-weight women, the underweight women not
only had 0.80 SD lower ESR1 expression (adjusted mean
difference = −2.24; 95% CI: −3.81, −0.67 vs. 0), but 0.77
SD lower PGR expression as well (adjusted meandifference = −2.31; 95% CI: −3.98, −0.64). No associa-
tions of BMI with ERBB2 expression were observed.
When stratifying by menopausal status, the postmeno-
pausal group had similar patterns of association to the
overall cohort (Table 3). Highly obese women had tu-
mors with 0.47 SD higher expression of proliferation
genes compared with normal-weight women (adjusted
mean difference = 0.54; 95% CI: 0.21, 0.86), yet mildly
obese (adjusted mean difference = 0.17; 95% CI: −0.09,
0.42) and overweight (adjusted mean difference = 0.18;
95% CI: −0.04, 0.40) women did not (0.15 SD and 0.16
SD, respectively). In contrast, being highly obese was as-
sociated with 0.34 lower ESR1 expression (adjusted
mean difference = −0.97; 95% CI: −1.61, −0.32) compared
with normal weight, whereas being mildly obese (adjusted
mean difference = 0.10; 95% CI: −0.38, 0.57) and over-
weight (adjusted mean difference = −0.10; 95% CI: −0.47,
0.26) were not (0.03 SD and 0.03 SD, respectively). Finally,
being underweight compared with normal weight was as-
sociated with 0.83 SD lower PGR expression (adjusted
mean difference = −2.46; 95% CI: −4.29, −0.62). We also
examined expression levels in the very highly obese
(≥40 kg/m2) postmenopausal women. Lower ESR1 expres-
sion and higher proliferation gene expression were
observed at similar levels in both the highly obese (35–
40 kg/m2) and very highly obese (>40 kg/m2) women
compared with normal-weight women (data not shown).
Table 3 Adjusted mean difference in gene expression levels by BMI, overall and by menopausal status
Overalla Premenopausala Postmenopausala
ESR1 Total n Mean Diff 95% CI Total n Mean Diff 95% CI Total n Mean Diff 95% CI
BMI (kg/m2)
Underweight (<18.5) 13 -2.24 -3.81, -0.67 5 -3.90 -6.44, -1.36 8 -1.45 -3.24, 0.33
Normal weight (18.5-24.9) 658 Ref 179 Ref 427 Ref
Overweight (25.0-29.9) 509 -0.12 -0.42, 0.19 112 -0.12 -0.75, 0.52 364 -0.10 -0.47, 0.26
Mildly Obese (30.0-34.9) 290 0.03 -0.36, 0.41 82 -0.12 -0.80, 0.56 195 0.10 -0.38, 0.57
Highly Obese (≥35.0) 206 -0.95 -1.47, -0.42 50 -0.96 -1.97, 0.05 141 -0.97 -1.61, -0.32
p for interaction=0.73
Overalla Premenopausala Postmenopausala
PGR Total n Mean Diff 95% CI Total n Mean Diff 95% CI Total n Mean Diff 95% CI
BMI (kg/m2)
Underweight (<18.5) 13 -2.31 -3.98, -0.64 5 -2.02 -5.23, 1.20 8 -2.46 -4.29, -0.62
Normal weight (18.5-24.9) 658 Ref 179 Ref 427 Ref
Overweight (25.0-29.9) 509 -0.20 -0.62, 0.22 112 -0.08 -0.95, 0.79 364 -0.15 -0.65, 0.35
Mildly Obese (30.0-34.9) 290 0.38 -0.11, 0.88 82 1.03 0.10, 1.96 195 0.21 -0.38, 0.81
Highly Obese (≥35.0) 206 -0.13 -0.81, 0.55 50 0.49 -0.70, 1.68 141 -0.34 -1.18, 0.50
p for interaction=0.25
Overalla Premenopausala Postmenopausala
ERBB2 Total n Mean Diff 95% CI Total n Mean Diff 95% CI Total n Mean Diff 95% CI
BMI (kg/m2)
Underweight (<18.5) 13 -0.27 -1.14, 0.60 5 -0.35 -2.14, 1.45 8 -0.22 -1.12, 0.68
Normal weight (18.5-24.9) 658 Ref 179 Ref 427 Ref
Overweight (25.0-29.9) 509 -0.01 -0.16, 0.18 112 0.26 -0.14, 0.65 364 -0.04 -0.24, 0.16
Mildly Obese (30.0-34.9) 290 -0.08 -0.28, 0.13 82 0.10 -0.32, 0.52 195 -0.09 -0.34, 0.16
Highly Obese (≥35.0) 206 -0.04 -0.32, 0.23 50 -0.16 -0.67, 0.35 141 0.03 -0.32, 0.37
p for interaction=0.68
Overalla Premenopausala Postmenopausala
Proliferation Total n Mean Diff 95% CI Total n Mean Diff 95% CI Total n Mean Diff 95% CI
BMI (kg/m2)
Underweight (<18.5) 13 0.17 -0.65, 1.00 5 0.33 -0.42, 1.09 8 0.02 -1.18, 1.21
Normal weight (18.5-24.9) 658 Ref 179 Ref 427 Ref
Overweight (25.0-29.9) 509 0.18 -0.01, 0.36 112 0.01 -0.32, 0.34 364 0.18 -0.04, 0.40
Mildly Obese (30.0-34.9) 290 0.16 -0.06, 0.38 82 -0.10 -0.47, 0.28 195 0.17 -0.09, 0.42
Highly Obese (≥35.0) 206 0.44 0.18, 0.71 50 -0.09 -0.53, 0.36 141 0.54 0.21, 0.86
p for interaction=0.06
aFrom linear regression, adjusted for age at diagnosis , race/ethnicity, moderate-vigorous physical activity, AJCC tumor stage, and study.
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0.37 SD lower, yet borderline significant, ESR1 expression
among the highly obese (adjusted mean difference = −0.96;
95% CI: −1.97, 0.05), while ESR1 expression was 1.5 SD
significantly lower among the underweight (adjusted mean
difference = −3.90; 95% CI: −6.44, −1.36). There was no as-
sociation between BMI and expression of proliferation
genes. Effect modification of the proliferation associations
by menopausal status was borderline statistically signifi-
cant (p for interaction = 0.06).The associations of BMI with intrinsic subtype are
given in Table 4. In models adjusted for age, race/ethnicity,
moderate-vigorous physical activity, AJCC stage, and
study, breast cancer patients with Basal-like tumors had
over triple the odds of being highly obese (≥35 kg/m2) vs.
normal weight compared to those with Luminal A tumors
(OR = 3.75; 95% CI: 1.97, 7.12). Women with Luminal B
tumors also had increased odds of being highly obese
compared to those with Luminal A tumors (OR = 2.44;
95% CI: 1.24, 4.79). There was little evidence for increased
Table 4 Association of BMI around breast cancer diagnosis with PAM50 intrinsic subtype, overall and by menopausal
status
Total n
PAM50 Intrinsic Subtype - Overalla
Luminal A Luminal B Basal-like HER2-E Normal-like
% % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
BMI (kg/m2)
Underweight (<18.5) 13 0.4 1.0 0.56 0.07, 4.79 1.2 7.44 2.03, 27.32 0.2 0.73 0.09, 5.93 0.0 Not calculable
Normal weight (18.5-24.9) 658 43.0 34.0 Ref 30.6 Ref 41.3 Ref 41.3 Ref
Overweight (25.0-29.9) 509 28.6 34.1 1.72 1.10, 2.71 28.8 1.71 1.13, 2.61 29.6 1.07 0.69, 1.64 33.8 1.13 0.42, 3.05
Mildly Obese (30.0-34.9) 290 20.8 17.0 1.14 0.67, 1.95 19.4 1.38 0.81, 2.36 15.3 0.72 0.41, 1.29 21.5 1.10 0.35, 3.51
Highly Obese (≥35.0) 206 7.6 13.9 2.44 1.24, 4.79 20.0 3.75 1.97, 7.12 13.5 1.97 0.99, 3.89 3.4 0.45 0.11, 1.85
Total n
PAM50 Intrinsic Subtype - Premenopausala,b
Luminal A Luminal B Basal-like HER2-E Normal-like
% % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
BMI (kg/m2)
Underweight (<18.5) 5 0.3 2.7 Not calculable 1.6 9.70 1.22, 77.39 1.0 3.83 0.36, 41.95 0.0 Not calculable
Normal weight (18.5-24.9) 179 41.3 40.6 Ref 36.3 Ref 46.9 Ref 19.9 Ref
Overweight (25.0-29.9) 112 27.2 33.7 1.77 0.69, 4.52 27.4 1.20 0.52, 2.79 22.3 0.87 0.35, 2.16 26.7 2.96 0.41, 21.51
Mildly Obese (30.0-34.9) 82 22.5 17.0 0.85 0.31, 2.32 20.2 0.74 0.31, 1.79 14.5 0.50 0.18, 1.38 45.4 4.00 0.63, 25.42
Highly Obese (≥35.0) 50 9.0 6.0 0.97 0.21, 4.49 14.5 1.31 0.43, 4.03 15.2 1.92 0.53, 6.96 8.0 2.21 0.28, 17.67
Total n
PAM50 Intrinsic Subtype - Postmenopausala,b
Luminal A Luminal B Basal-like HER2-E Normal-like
% % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
BMI (kg/m2)
Underweight (<18.5) 8 0.4 0.2 0.82 0.10, 6.62 1.1 6.97 1.09, 44.38 0.0 Not calculable 0.0 Not calculable
Normal weight (18.5-24.9) 427 41.9 30.9 Ref 26.8 Ref 39.4 Ref 44.1 Ref
Overweight (25.0-29.9) 364 29.4 34.4 1.79 1.04, 3.08 29.0 1.94 1.13, 3.34 30.3 1.08 0.65, 1.82 38.6 1.20 0.39, 3.63
Mildly Obese (30.0-34.9) 195 21.6 16.5 1.07 0.56, 2.05 18.8 1.59 0.74, 3.43 16.7 0.77 0.38, 1.56 14.9 0.73 0.19, 2.75
Highly Obese (≥35.0) 141 7.2 18.0 3.10 1.44, 6.68 24.3 6.12 2.81, 13.35 13.6 2.01 0.90, 4.48 2.4 0.29 0.04, 1.83
aFrom multinomial logistic regression with comparison group = Luminal A, adjusted for age at diagnosis, race/ethnicity, moderate-vigorous physical activity, AJCC
tumor stage, and study.
bp for interaction=0.52.
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(OR = 1.38; 95% CI: 0.81, 2.36) and Luminal B (OR =
1.14; 95% CI: 0.67, 1.95) tumors. While women with
Basal-like and Luminal B tumors had increased odds of
being overweight, the odds were of lower magnitude
compared with being highly obese. Similarly, cases with
Basal-like tumors had elevated odds of being under-
weight compared with those with Luminal A tumors
(OR = 7.44; 95% CI: 2.03, 27.32). However, the number
of underweight women was small (n = 13) and made the
confidence interval wide for this association, thus limit-
ing the interpretation of this result.
In stratified analyses of BMI and intrinsic subtype by
menopausal status (Table 4), the postmenopausal group
had patterns of association similar to the overall cohort.
These same relationships were not present in the premen-
opausal group, although no effect modification by meno-
pausal status was observed (p for interaction = 0.52).Discussion
In this cohort study of 1,676 breast cancer survivors, we
found that extreme obesity around breast cancer diagnosis
was positively associated with poorer prognostic gene ex-
pression profiles and tumor subtypes. Highly obese
women were more likely to have tumors with greater ex-
pression of proliferation genes, and lower expression of
ESR1, which are characteristics of the Basal-like subtype.
Correspondingly, compared to women with the Luminal
A intrinsic subtype, those with the Basal-like subtype and
Luminal B subtype had increased odds of being highly
obese (≥35 kg/m2) around breast cancer diagnosis. We did
not find comparable associations among women who were
overweight or mildly obese. The association with prolifera-
tion gene expression was observed in postmenopausal but
not premenopausal women. To our knowledge, ours is the
first study to examine the association of different levels of
obesity with tumor gene expression.
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m2) around breast cancer diagnosis, while strongly and
positively associated with both proliferation-related gene
expression and associated intrinsic subtypes (Basal-like
and Luminal B), was negatively associated with estrogen-
related gene expression and associated intrinsic subtypes
(Luminal A). Surprisingly, the latter finding is potentially
inconsistent with the notion that among postmenopausal
women, obesity is generally associated with higher plasma
levels of estradiol from adipose tissue [31] and greater risk
of ER+ (primarily Luminal A) breast cancer [32,33], and
suggests that even if higher circulating estradiol is avail-
able in postmenopausal women, the tumor itself may be
less responsive to endogenous estrogen depending on level
of obesity. In a study of adipose gene expression and
weight loss changes in postmenopausal women, greater
weight loss was associated with borderline increased ESR1
expression (p for trend = 0.08) that could be possibly at-
tributed to reduced adipose tissue inflammation [34].
Thus, perhaps at some threshold level of increasing obes-
ity, tumor growth could be fueled by heightened inflam-
matory processes, rather than estrogen exposure, thus
leading to decreased ESR1 expression and lower likelihood
of developing the associated intrinsic subtypes. Finally,
while we found that the associations for subtype might
also be present in the overweight but not the mildly obese
group, the magnitude of association was much smaller
and could be due in part to chance.
Our observation of a possible threshold effect at high
BMI being associated with a proliferative tumor gene ex-
pression profile, and development of Basal-like and Lu-
minal B tumors, is consistent with our previous work
which identified highly obese (≥40 kg/m2) breast cancer
patients being at greatest risk for poorer prognosis and
survival [22,35]. While the underlying biological mech-
anism linking obesity to tumor etiology is unclear, there
are some intriguing and plausible hypotheses. Obesity
can influence cancer risk by increased production of in-
flammatory factors, insulin and insulin-like growth fac-
tors (IGFs), and altered adipokines, resulting in a state
of low-grade chronic inflammation [36]. Higher activity
of the phosphatidylinositol 3-kinase (PI3K)-Akt path-
way, which primarily regulates cellular proliferation,
migration, and survival [37], has been well-described in
Basal-like tumors [38-40]. Thus, perhaps higher levels
of insulin and IGFs in the highly obese can drive the
growth of Basal-like tumors, but not Luminal tumors,
through this pathway [41,42]. Furthermore, higher cir-
culating glucose levels in the highly obese could poten-
tially support biosynthesis of Basal-like tumors, which
have been shown to be more glycolytic than other
tumor subtypes [43].
While we observed some intriguing associations
among the underweight, including lower expression ofESR1 and PGR and being more likely to have a Basal-
like tumor, we were limited by the small number of
underweight women in our cohort (n = 13) to draw any
definitive conclusions about this subgroup. To date, the
role of underweight and tumor gene expression is largely
unknown.
Strengths of this study include being the first to examine
the relationship between obesity around breast cancer
diagnosis and tumor gene expression, thus investigating
potential molecular mechanisms of obesity on tumorigen-
esis. Given recent findings from large epidemiologic stud-
ies on high obesity and underweight, but not overweight
or mild obesity being associated with poorer prognosis
and survival [11,22,35], we were also able to examine the
association of varying degrees of obesity in relation to sub-
type and gene expression. Finally, we used the PAM50
assay, which is a classification tool that has been shown to
have better prognostic ability than surrogate IHC classifi-
cation methods [23,26].
Several limitations should be noted. Weight and height
were self-reported, yet substantial agreement between
BMI based on self-reported, compared with measured,
weight and height has been shown [44]. Also, the number
of underweight women in our cohort was small (n = 13).
However, we chose to keep the underweight group as a
separate category, as we have previously observed elevated
risks of breast cancer mortality in underweight women
[22,35] and considered this analysis of obesity and gene
expression exploratory. This was a cross-sectional analysis,
thus causality could not be inferred between obesity
around breast cancer diagnosis and tumor intrinsic sub-
type and gene expression. In addition, BMI reflects the re-
lationship of weight to height and thus does not reflect
between-individual variation in total adiposity [45] and
metabolic risk profiles [46].
One should also consider that perhaps it is not weight
at one timepoint around breast cancer diagnosis, but ra-
ther weight trajectories over the life course that may act
on gene expression or tumor subtype [47]. Furthermore,
compared with non-Hispanic Whites, African Americans
and Hispanics are more likely to be obese [48,49], and
African Americans are more likely to be diagnosed with
poor prognosis subtypes [25,50,51]. Given these associa-
tions, as a sensitivity analysis, we restricted the statistical
models to Whites only, and both subtype and gene ex-
pression results were essentially unchanged. Finally,
LACE women were enrolled on average two years post-
diagnosis, thus women with better prognosis subtypes
(Luminal A) could have been more likely to survive to en-
rollment whereas those with poorer prognosis subtypes
(Basal-like) were not. However, we found in other analyses
that this potential survival bias was minimal [23], and
again when we restricted the analyses by individual cohort,
the results were similar (Additional files 1 and 2).
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Among women with breast cancer, particularly postmen-
opausal women, those who were highly obese, but not
mildly obese, around breast cancer diagnosis were more
likely to have breast tumors with greater expression of
proliferation genes and lesser expression of ESR1, and pos-
sible increased odds of being diagnosed with Basal-like
and Luminal B tumor subtypes. These findings suggest
that etiology of tumor subtypes may vary by degree of pre-
existing obesity of the patient and propose novel insights
into molecular mechanisms linking obesity, ER expression,
and proliferation to breast tumor development.Additional files
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